A lot to like now organic growth has turned

Q1e: earnings beat as Network Solutions returned to org. growth. We raise '24e-'26e adj. EBITDA-capex by 3-4% on 3-4% higher sales. Low valuation, fruitful cost savings and easy comps: up to BUY (Hold).

Tough comps, but solid underlying progress

Enea AB: 1 director

A director at Enea AB bought 10,000 shares at 39.900SEK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board memb...

Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024

Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.

The weekly navigator

From the past week, we highlight: 1) we raised our target price on Latour to SEK285 (280), but reiterated our HOLD; 2) Kinnevik-owned Lunar raised SEK282m of new capital; and 3) we will host an investor lunch with Latour’s CEO Johan Hjertonsson at our Stockholm office next week.

Aker BP (Buy, TP: NOK290.00) - Capex concerns looming

While investor concerns appear tilted towards a near-term production decline, we are increasingly concerned that consensus FCF will face meaningful negative revisions, as capex assumptions beyond 2026 look far too low. For 2027–2030, our FCF estimates are ~40% below consensus. We reiterate our BUY, but have cut our target price to NOK290 (325) on a lower fair P/NAV.